Sopharma AD-Sofia (WAR:SPH) Cyclically Adjusted Revenue per Share: zł27.56 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:SPH Sopharma AD-Sofia WAR:SPH
66 GF Score
Price zł7.52
GF Value zł13.21
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Sopharma AD-Sofia Cyclically Adjusted Revenue per Share?

Sopharma AD-Sofia WAR:SPH -1.04% 66 Cyclically Adjusted Revenue per Share is zł27.56 as of Mar. 2026. GuruFocus rates WAR:SPH with a GF Score™ of 66/100 and a GF Value™ of zł13.21 (Possible Value Trap). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Sopharma AD-Sofia's adjusted revenue per share for the three months ended in Mar. 2026 was zł2.757. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is zł27.56 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Sopharma AD-Sofia's average Cyclically Adjusted Revenue Growth Rate was 1.90% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 6.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Sopharma AD-Sofia was 7.60% per year. The lowest was 6.50% per year. And the median was 7.05% per year.

As of today (2026-08-17), Sopharma AD-Sofia's current stock price is zł7.52. Sopharma AD-Sofia's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was zł27.56. Sopharma AD-Sofia's Cyclically Adjusted PS Ratio of today is 0.27.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Sopharma AD-Sofia was 1.28. The lowest was 0.27. And the median was 0.93.


Sopharma AD-Sofia  (WAR:SPH) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Sopharma AD-Sofia's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=7.52/27.56
=0.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Sopharma AD-Sofia was 1.28. The lowest was 0.27. And the median was 0.93.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Sopharma AD-Sofia Cyclically Adjusted Revenue per Share Related Terms


Sopharma AD-Sofia Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Sopharma AD-Sofia's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sopharma AD-Sofia Cyclically Adjusted Revenue per Share Chart

Sopharma AD-Sofia Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.63 10.80 14.25 13.06 29.11

Sopharma AD-Sofia Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.63 13.42 30.03 29.11 27.56

WAR:SPH vs MCK, COR, CAH: Cyclically Adjusted Revenue per Share Comparison

For the Medical Distribution subindustry, Sopharma AD-Sofia's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sopharma AD-Sofia Cyclically Adjusted PS Ratio vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Sopharma AD-Sofia's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Sopharma AD-Sofia's Cyclically Adjusted PS Ratio falls into.


WAR:SPH
66GF Score
Sopharma AD-Sofia WAR:SPH
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sopharma AD-Sofia Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Sopharma AD-Sofia's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=2.757/330.2130*330.2130
=2.757

Current CPI (Mar. 2026) = 330.2130.

Sopharma AD-Sofia Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201603 3.529 238.132 4.894
201606 3.433 241.018 4.703
201609 3.534 241.428 4.834
201612 3.855 241.432 5.273
201703 3.773 243.801 5.110
201706 3.808 244.955 5.133
201709 4.399 246.819 5.885
201712 5.281 246.524 7.074
201803 5.438 249.554 7.196
201806 4.888 251.989 6.405
201809 5.137 252.439 6.720
201812 5.446 251.233 7.158
201903 5.341 254.202 6.938
201906 5.085 256.143 6.555
201909 5.176 256.759 6.657
201912 6.008 256.974 7.720
202006 0.000 257.797 0.000
202009 5.918 260.280 7.508
202012 7.721 260.474 9.788
202103 6.606 264.877 8.235
202106 6.912 271.696 8.401
202109 7.270 274.310 8.752
202112 7.306 278.802 8.653
202203 6.830 287.504 7.845
202206 6.822 296.311 7.603
202209 6.347 296.808 7.061
202212 6.485 296.797 7.215
202303 7.653 301.836 8.372
202306 7.392 305.109 8.000
202309 6.583 307.789 7.063
202312 6.342 306.746 6.827
202403 8.034 312.332 8.494
202406 5.043 314.175 5.300
202409 5.587 315.301 5.851
202412 7.346 315.605 7.686
202503 7.931 319.799 8.189
202506 8.062 322.561 8.253
202509 2.733 324.800 2.779
202512 2.972 324.054 3.028
202603 2.757 330.213 2.757

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of zł27.56 mean?
Sopharma AD-Sofia (WAR:SPH) has a Cyclically Adjusted Revenue per Share of zł27.56 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Sopharma AD-Sofia and its competitors.
Is Sopharma AD-Sofia's Cyclically Adjusted Revenue per Share too high?
Sopharma AD-Sofia's current Cyclically Adjusted Revenue per Share is zł27.56. Overall, Sopharma AD-Sofia has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sopharma AD-Sofia's Cyclically Adjusted Revenue per Share compare to MCK and COR?
Sopharma AD-Sofia's Cyclically Adjusted Revenue per Share of zł27.56 can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Distribution company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Distribution industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Sopharma AD-Sofia and its competitors. Sopharma AD-Sofia's current Cyclically Adjusted Revenue per Share is zł27.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sopharma AD-Sofia stock overvalued right now?
Based on GuruFocus' analysis, Sopharma AD-Sofia (WAR:SPH) is currently considered Possible Value Trap. The stock's GF Value™ is zł13.21, compared to a current price of zł7.52 — trading 43.1% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is zł27.56. Sopharma AD-Sofia's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Sopharma AD-Sofia (WAR:SPH), the current Cyclically Adjusted Revenue per Share is zł27.56 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sopharma AD-Sofia (WAR:SPH) Overvalued in 2026?

Based on GuruFocus' analysis, Sopharma AD-Sofia stock appears to be undervalued. The current stock price of zł7.52 is trading 43.1% below its estimated GF Value™ of zł13.21. GuruFocus considers Sopharma AD-Sofia to be Possible Value Trap.

Key valuation signals for WAR:SPH:

  • Cyclically Adjusted Revenue per Share: zł27.56
  • GF Value™: zł13.21 vs. price of zł7.52 (43.1% below fair value)
  • GF Score™: 66/100 with 4 warning signs

No single metric tells the full story. See the WAR:SPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sopharma AD-Sofia Business Description

Other Exchanges 3JR:GermanySFA:Bulgaria
Address 5 Lachezar Stanchev Street, Sopharma Business Towers, Building A, Floor 12, Sofia, BGR, 1756
Sopharma AD-Sofia is a company engaged in the production of pharmaceutical products. Its principal activities include the production and trade of medicinal substances and finished drug forms; and research and development as well as engineering and implementation activities in the field of medicinal products. It is also focused on the distribution of pharmaceuticals like medical supplies, sanitary materials, vitamins, food supplements, and cosmetics. The company's segments are the Production of pharmaceutical products; Distribution of pharmaceutical products. It generates the majority of its revenue from the Distribution of pharmaceutical products.
66GF Score

Get the complete analysis for WAR:SPH

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł7.52
Price
zł13.21
GF Value